Pharmaceuticals company Mylan, which distributes the Epipen, a device for severe allergic reactions, is back in the news.
Mylan on Friday disclosed a possible defect in some of the devices, months after embroiling itself in controversy and a congressional investigation last year by dramatically raising the list price of the life-saving injector to over $600 for a pack of two.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.